Wegovy: Weight loss drug to be available from GPs in pilot scheme
BMJ 2023; 381 doi: https://doi.org/10.1136/bmj.p1308 (Published 08 June 2023) Cite this as: BMJ 2023;381:p1308- Gareth Iacobucci
- The BMJ
GPs in England will be able to prescribe a weight loss drug to patients with obesity as part of a new £40m government pilot designed to widen access to the treatment.
Earlier this year the National Institute for Health and Care Excellence recommended the use of semaglutide (Wegovy) by adults who have at least one weight related comorbidity and a BMI of at least 35.1 The drug, a weekly self-administered injection, works by suppressing appetite by mimicking the hormone glucagon-like peptide-1 (GLP-1). Other weight loss drugs are currently under consideration in clinical trials.
NICE has stipulated that semaglutide be available only within the NHS’s specialist weight management services, in conjunction with a reduced calorie diet and increased physical activity. This means …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.